IVA logoIVA
Inventiva - ADR

483
Loading...
Loading...
News
all
press releases
How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%
The mean of analysts' price targets for Inventiva (IVA) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·12d ago
News Placeholder
More News
News Placeholder
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks·3mo ago
News Placeholder
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva secures 94.1M in financing, potentially reaching 348M, to fund the Phase 3 NATiV3 trial for lanifibranor in NASH. Leadership changes include new chairman and director appointments. read...
Benzinga·11mo ago
News Placeholder
Inventiva Advances Lanifibranor Trial with Promising Data
Inventiva (IVA) has released an update. Inventiva reports strong progress in its NATiV3 Phase III clinical trial for lanifibranor, with over 80% en...
TipRanks Financial Blog·1y ago
News Placeholder
FY2025 Earnings Forecast for Inventiva S.A. (NASDAQ:IVA) Issued By HC Wainwright
Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Inventiva in a report issued on Monday...
Zolmax·1y ago
News Placeholder
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), April 3, 2024 Inventiva (Euronext Paris and Nasdaq: IVA) (the Company ), a clinical-stage biopharmaceutical company focused on the...
Globe Newswire·1y ago
News Placeholder
Brokerages Set Inventiva S.A. (NASDAQ:IVA) Price Target at $15.67
Inventiva S.A. (NASDAQ:IVA - Get Free Report) has been given an average recommendation of "Buy" by the eight brokerages that are covering the firm, MarketBeat.com reports. Eight investment analysts...
Ticker Report·1y ago
News Placeholder
Buy Rating Affirmed: Inventiva's Progress and Promise in Lanifibranor's Clinical Trials
Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Inventiva (IVA Research Report), retaining the price target of $22.00. Ed Arce has...
TipRanks Financial Blog·1y ago
News Placeholder
Full Year 2023 Inventiva SA Earnings Call Transcript
Related Stocks: OTCPK:IVEVF...
GuruFocus·1y ago
News Placeholder
Inventiva SA (IVA, $3.67) price exceeded its 50-day Moving Average on March 28, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·1y ago

Latest IVA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.